The biggest technical challenge for adaptive deep brain stimulation (aDBS) is how small brain signals are, Medtronic's Scott ...

Medtronic (NYSE:MDT) has won FDA approval for a deep brain stimulation system for Parkinson’s disease. The approval is for ...

The FDA approves BrainSense Adaptive deep brain stimulation and electrode identifier technology for the treatment of ...

T here is still no cure for Parkinson’s disease, but the U.S. Food and Drug Administration (FDA) approved a new deep brain ...

Shortly after obtaining a greenlight in Europe and after more than 10 years in development, Medtronic has now received the ...

The FDA’s authorisation of Medtronic’s BrainSense follows the system’s receipt of a CE mark in Europe last month.

The FDA has approved BrainSense, an adaptive deep brain stimulation system that can adjust therapy for Parkinson’s disease in ...

The company's adaptive deep brain stimulation technology for Parkinson's disease therapy is expected to be available ...

For the one million people diagnosed with Parkinson's disease in the United States1, Medtronic plc (NYSE:MDT), a global ...

The "U.S. Deep Brain Stimulation In Parkinson's Disease Market Size, Share & Trends Analysis Report By Product ...

Medtronic (MDT) announced FDA approval of BrainSense Adaptive deep brain stimulation – aDBS – and BrainSense Electrode Identifier. There is no ...

The FDA approved Medtronic's BrainSense Adaptive DBS and Electrode Identifier for Parkinson's, enhancing therapy ...